Single nucleotide polymorphisms in fibroblast growth factor 23 gene, FGF23, are associated with prostate cancer risk
- To determine whether sequence variants within the FGF23 gene are associated with the risk of developing prostate cancer in a Korean population.
Patients and Methods
- Five common single nucleotide polymorphisms (SNPs) in the FGF23 gene were assessed in 272 patients with prostate cancer and 173 control subjects with benign prostatic hyperplasia.
- Single-locus analyses were conducted using conditional logistic regression.
- In addition, we performed a haplotype analysis for the five FGF23 SNPs tested.
- Three SNPs in the FGF23 gene (rs11063118, rs13312789 and rs7955866) were associated with an increased risk of prostate cancer in our study population.
- Odds ratios for homozygous variants vs wild-type variants ranged from 1.68 (95% confidence interval [CI]: 1.15–2.46) to 1.79 (95% CI: 1.16–2.75).
- This is the first study showing that genetic variations in FGF23 increase prostate cancer susceptibility.